Blog / Ownership

ASC Private Equity in 2027: Roll-Ups, Multiples and What It Means for Owners

Why platforms trade at 11 to 17 times EBITDA while single centers trade at 5 to 8, and what that gap should change in your next decision.

ASC private equity in 2027: current multiples, roll-up structures, management fees and the diligence owners need before any term sheet.

ASC Private Equity in 2027: Roll-Ups, Multiples and What It Means for Owners

ASC private equity interest in 2027 comes down to one number: platforms now trade at 11 to 17 times EBITDA, while a single center sells for 5 to 8 times (FOCUS Investment Bankers, April 2026). That spread is most of the story behind why capital keeps moving into ambulatory surgery, and it matters whether an owner is selling this year or just watching the market.

Why capital wants ASC capacity

The US ASC market is about $45.3 billion in 2025 and is projected to grow at a 6.1% compound rate to $72.7 billion by 2033 (Grand View Research). About 6,400 Medicare-certified centers operate today, and roughly 62% of market revenue sits in physician-owned centers, with the remainder split across hospital, corporate and joint venture ownership (MedPAC; Grand View Research, 2025).

Two forces explain the appetite. First, site of service: Medicare, commercial payers and patients generally pay less for the same procedure in an ASC than in a hospital outpatient department, and the CY2026 rule added 560 procedures to the ASC covered list, 271 of them moved off the inpatient only list (CMS, November 2025). Second, case migration: total joints, spine and cardiology cases that were inpatient five years ago are now routine in well-run centers. Every procedure that migrates is a procedure a buyer can underwrite into a model.

Google search interest in "surgery center" in the US reached its highest point in five years during 2026, up about a quarter over the 2021 to 2024 average (Google Trends), one more sign that attention, not just capital, is moving toward this setting.

What the multiples actually reward

Buyers are not pricing revenue. They are pricing margin, and the margin gap between a small center and a large one is wide: EBITDA margin runs 12.8% for centers under $3 million in revenue and 37.3% for centers over $9 million (Avanza). A ten-center platform running at 30% margins is worth more per dollar of EBITDA than a single center running at 15%, because the buyer is paying for the operating discipline along with the asset.

ASC valuation multiples by deal type, 2026 (FOCUS Investment Bankers, April 2026)
Deal typeTypical EBITDA multiple
Single-specialty ASC5 to 8x
Multi-specialty ASC6 to 10x
Multi-site platform11 to 17x

The practical read: an owner who sells a single center at the bottom of its margin range is selling at the bottom of its multiple range too. Case costing exists for a reason that has nothing to do with a deal; it is the same number a buyer uses to set price, and it should already be driving decisions long before a term sheet shows up.

What a roll-up actually buys, and what it costs

Private equity platforms and management companies rarely buy a center outright and walk away. The common structure pairs an equity position with a management fee, commonly reported in the range of 4% to 7% of net revenue (industry convention, commonly reported). That fee funds centralized supply contracting, staffing pools, payer contracting and back-office systems, the same scale advantages behind the 37.3% margin posted by large centers against 12.8% for small ones (Avanza).

For illustration, a center generating $6 million in net revenue would pay $240,000 to $420,000 a year in management fees at that range, money that comes out of distributable margin regardless of how the equity performs. For a fuller look at what these companies do and how fee structures compare, see ASC Management Companies: What They Do, What They Typically Charge and How to Compare Them.

Physician ownership also carries a federal requirement that matters in any deal structure: physician investors must meet safe harbor conditions, the most practical of which is that each owner performs a meaningful share of their procedures at the center. A platform deal that dilutes a physician below that threshold changes the compliance picture along with the cap table, not just the economics.

Site neutrality and the inpatient only phase-out are changing what gets bought

Two Medicare policy threads are reshaping which centers look attractive to buyers. The inpatient only list is being eliminated over three years starting in 2026, with musculoskeletal procedures going first under a new payment classification (CMS, November 2025). Site neutral payment policy, which pays the same rate for the same service regardless of setting, is expanding, and hospital outpatient rates are generally still higher than ASC rates for the same procedure under current policy (MedPAC). As that gap narrows, hospitals have more reason to want ASC capacity rather than compete against it, which is part of why joint ventures sit alongside straight private equity acquisition as an active structure in 2027.

A center whose surgeons already perform complex orthopedic and spine cases, the specialties most affected by the inpatient only phase-out, is a different acquisition target now than it was in 2023. Buyers are underwriting the procedures a center's surgeons can add under the new covered list, not only the cases on today's schedule.

Before you take a term sheet

A letter of intent arrives with a multiple attached, and that multiple is built on trailing EBITDA. Three things change that number more than anything else a seller can do in the weeks before a deal closes:

  • Know contribution margin by procedure and by payer. A buyer's diligence team will build this model with or without the seller; owners who already have it negotiate from the same information the buyer holds.
  • Know where the center sits against the core operating benchmarks: block utilization, first case starts, supply cost per case, denial rate and the rest. A center at the 90th percentile for supply cost (36.8% of revenue against a 26.4% median) is leaving margin, and therefore multiple, on the table (Avanza, 2022).
  • Get counsel on the safe harbor and certificate of need questions before signing anything. Thirty-five states plus the District of Columbia run some form of certificate of need program, and several exempt ASCs or apply lighter review; confirm which applies before ownership structure changes hands (AHPA/NCSL, 2025).

Centers planning to open or expand ahead of a sale should run the same pro forma discipline a new build requires: surgeon volume commitments, payer mix, and contribution margin by procedure before any lease or term sheet is signed. That process is covered in How to Open an ASC in 2027, and it applies as much to an expansion ahead of a sale as to a ground-up build.

Owners who want the broader picture of how ASCs are owned and who sits where in that structure can start with What Is an Ambulatory Surgery Center (ASC)? Definition, Economics and Who Owns Them, and centers preparing financial and clinical records for diligence should work through ASC Compliance Checklist 2027: Licensing, Medicare Conditions for Coverage and Life Safety well ahead of a buyer's first request list. A surgery center consultant can also help frame the diligence question list before advisors are retained; see Surgery Center Consultants: When to Hire One, What to Ask and What It Should Cost.

What to do this quarter

  1. Build contribution margin by procedure and by payer for the center's top 20 cases, using actual consumption rather than preference cards. This is the number a buyer prices, and it should already be driving surgeon and payer conversations regardless of any sale.
  2. Run the center against the core operating benchmarks, particularly supply cost per case and EBITDA margin by revenue size, and fix the largest gap before any conversation with a buyer or management company starts.
  3. If a platform or management company term sheet is on the table, model the management fee against three years of projected net revenue before comparing multiples, and get independent counsel on the physician ownership safe harbor question before signing.

Make your ASC more profitable

Sigmatic is a team of ASC consultants who use our own technology to manage surgery centers: better margins, better workflows, and a real-time view of cost per case and utilization that keeps the gains in place. If the numbers in this article look like your center, book a free 30-minute consultation and we will go through your own figures and show you where the margin is. Read the How to Open an ASC in 2027 guide, grab the free PDF, The 2027 ASC State of the Union: maximizing profit on razor-thin margins, from the form on this page, or email [email protected].

Free guide

The 2027 ASC State of the Union: Maximizing profit on razor-thin margins

16 pages of charts: the market, the 2026 reimbursement rules, the benchmarks that separate a 13 percent margin from a 37 percent one, a case costing method you can run this month and a 90-day plan.

One email with the PDF, then the occasional note on ASC margins. Unsubscribe any time.

Before you go

Want a more profitable ASC?

Book a free 30-minute consultation on your own numbers, or leave your email and we will send the 2027 guide first.

Make your ASC more profitable.

A free 30-minute consultation on your own numbers: where the margin is, what to fix first. No obligation.